Amycretin

What it is

Amycretin is a single peptide that activates both the GLP-1 receptor and the amylin receptor. The name is the two mechanisms stitched together, and the design goal is to get what CagriSema achieves with two co-formulated drugs from one molecule.

That is a meaningful engineering difference. One molecule means one pharmacokinetic profile, one manufacturing process, and one titration rather than two that have to be balanced against each other.

What the evidence shows

The phase 2 trial in people with type 2 diabetes reported in November 2025 was the first evaluation in that population. From a mean baseline weight of 99.2 kg, weekly subcutaneous amycretin produced up to 14.5% weight loss at 36 weeks against 2.6% on placebo, alongside HbA1c reductions of up to 1.8% from a baseline of 7.8%.

Two details matter more than the headline. The first is that this was a diabetes population, where every drug in this class produces less weight loss than it does in people without diabetes, so the obesity figures should be higher. The second is that the dose response showed no clear plateau at the top of the range, which is the same observation that made retatrutide interesting.

Phase 3 programmes in both diabetes and obesity were announced for 2026.

The oral version is the more interesting part

Amycretin has also been studied as an oral formulation. Delivering a peptide of this size orally with useful bioavailability is a genuinely hard problem, and the only real precedent in this class is oral semaglutide, which requires an absorption enhancer and a fasting window.

If an oral dual agonist works at competitive efficacy, it changes the shape of the market more than another injectable does. Orforglipron gets there by being a small molecule rather than a peptide, which is a different solution to the same problem.

Practical notes

• It is investigational, and that is the whole caveat. No long-term safety data exists, phase 3 has not read out, and nothing about a phase 2 result guarantees a phase 3 one.
• It is not obtainable, and anything sold under the name is not it. A molecule in Novo's phase 3 pipeline is not available through research suppliers.
• Watch the obesity readout, not the diabetes one. The 14.5% figure understates what this will likely do in people without diabetes, and the phase 3 obesity programme is the number that will matter.

Side effects and warning signs

Commonly reported

• Nausea and vomiting, dose-dependent and concentrated during titration
• Diarrhoea
• Reduced appetite
• Injection-site reactions

Stop and get medical help

• Personal or family history of medullary thyroid carcinoma or MEN2, pending full characterisation of this molecule
• Severe persistent abdominal pain radiating to the back
• This is an investigational compound with no long-term safety dataset, which is the main caution

Sources

1. Efficacy and safety of GLP-1 receptor agonists and co-agonists for weight loss in adults without diabetes, updated systematic review, Ann Intern Med 2026review
2. Novo Nordisk phase 2 trial with amycretin reports significant weight loss and HbA1c reduction in type 2 diabetesnews

From the community

Discussion for this compound concentrates in r/Semaglutide.

No threads cached yet.

Reddit removed unauthenticated API access, so this section is populated by a build-time script using your own API credentials. Run pnpm fetch:reddit with REDDIT_CLIENT_ID and REDDIT_CLIENT_SECRET set.